ATS Sells a Record Backlog, Not a Quarter: Section 38 Freezes Canadian Packaging Orders and Full-Year Guidance Quietly Disappears
Bookings +12.7%, record $1.2B life-sciences backlog, a radiopharma order win, and a withdrawn outlook — all in the same 90 minutes
ATSAF · Earnings Call · 2026-11-04
A funnel that got better while the P&L got worse
ATS's fiscal Q2 2027 (reported November 4) is the cleanest example in this cycle of a company whose demand signal and income statement decoupled. Order bookings came in at $827 million, up 12.7% year over year. Backlog sat at roughly $2 billion, with life sciences at $1.2 billion — the highest in company history — and life sciences, food & beverage and energy together making up more than 85% of the total. Trailing twelve-month book-to-bill was 1.05 to 1. That is solid backlog growth by any reasonable definition. And yet revenue fell 8.6% to $666 million, adjusted earnings from operations dropped 27.4% to $57.4 million, and the adjusted margin compressed from 10.9% to 8.6% on mix and absorption. Chief Executive Douglas Wright opened the call by conceding the obvious tension: “the strength of our end markets is visible, with strong growth in order bookings this quarter, especially in life sciences” — Douglas William Wright, Chief Executive Officer · 2026-11-04. The problem is that new factories take years, not quarters, to convert. That is why the guidance change is the real headline. Interim CFO Anne Cybulski did not bury it: “we do not expect to achieve our previous goals for modest revenue growth, and for margin expansion in the year” — Anne Cybulsk, Interim Chief Financial Officer · 2026-11-04. Q3 revenue is now guided to $640–680 million. The contrast with the prior quarter is stark. In August, Wright was still defending the full-year target with an explicit conditional: “we believe the modest organic revenue growth remains achievable, but it will depend on the timing of larger customer awards and the pace at which those orders convert during the second half” — Douglas Wright, Chief Executive Officer · 2026-08-06. The condition failed. What shipped in August as a hedged "modest growth" commitment is gone as of November.Section 38 — the tariff that ran the wrong direction
Most of 2026's tariff conversation in North America has been a windfall story. One of the highest-momentum global themes of the second calendar quarter was tariff refund, and it persisted through the third quarter as net tariff refunds — a net EPS benefit dozens of US reporters (Packaging Corp, JELD-WEN, KDP, HSIC, ACCO, Holiday Inn Vacations, to name a handful) have banked this year. ATS is the mirror image: a Canadian manufacturer that got tariffed *into* a demand freeze rather than refunded out of one. The company-specific detail matters. “The Section 38 tariffs that came into effect in late August after the breakdown of trade talks between Canada and the United States affected our packaging equipment, and delayed customer decision making in response to the tariffs” — Douglas William Wright, Chief Executive Officer · 2026-11-04 — packaging lines built in Canadian plants and sold into the US. It is not a life-sciences problem and not a structural one. Two months of the quarter were consumed by customers and ATS jointly trying to work out what the rules were. By late October the US had modified Section 38, eliminating the impact on nearly all covered products. Wright, notably, refused to size the release: “we literally just got the news a week ago when we just had an election last night” — Douglas William Wright, Chief Executive Officer · 2026-11-04, adding that packaging was "pretty material last year" but steering clear of quantifying the unlock. That refusal is defensible and frustrating in equal measure — it is the single most modelable piece of upside in the story and management will not hand it over.Radiopharma and the SMR option
The bullish counterweight is a genuine diversification of the life-sciences pipeline that has been building for at least three quarters. Radiopharma was the standout: “we did get a large incremental order in radiopharma and we are very happy with the performance sequential performance” — Douglas William Wright, Chief Executive Officer · 2026-11-04, alongside follow-on medical device work in diabetes care, vision care, sterilization and liquid pharma visual inspection. Excluding GLP-1, life sciences revenue actually grew year over year — GLP-1 has perhaps two more quarters of comp headwind before it laps. Nuclear is where ATS converges with a broader tape move. The global theme list is thick with nuclear industry and utility-adjacent demand: Cameco talking replacement-rate demand and gigawatt-scale reactors, Talen and Entergy discussing data center load contracting, Constellation and Talen on capacity markets. ATS sits underneath that build-out — CANDU refurbishment as the base, plus SMR fabrication and fuel handling. September brought the first US construction permit for a commercial SMR in Tennessee; Darlington is under construction in Ontario. The step change from prior calls is temporal. In February, SMRs were framed as a five-plus-year optionality: “we are also active on, I would call it, a handful -- a full handful of SMR customers in the early-stage activities in both modular fabrication and fuel handling” — Douglas Wright, Chief Executive Officer · 2026-02-04. Now ATS is booking with an existing SMR customer, adding a new one, and committing to US domestic manufacturing plus a UK entry methodology. That is a real, if slow-burning, upgrade.The surgical cost program — and the part the Street missed
The cost transformation program is the bridge to the 15% margin target, and management finally sized it properly: $65–75 million of annualized savings, roughly 250 basis points from a 10% base, with a 15-month implementation, a ~10% square-footage reduction, 300–400 heads including subcontractors, and payback under a year. Half the benefit lands in COGS, half in SG&A — a split that Cherilyn Radbourne of TD Cowen admitted the market had underappreciated:. Wright was emphatic that this is not a generic industrial haircut, and the framing is the most persuasive part of the call: “this is a very surgical exercise about where we are addressing floor space and workforce where the capacity was simply oversized to the available market opportunity” — Douglas William Wright, Chief Executive Officer · 2026-11-04. Capacity is coming out of Europe, food and residual transportation; capacity is going *in* at radiopharma (Bologna expanded, new service centers in the US Midwest and Melbourne). The awkward bit is the balance sheet. Net debt to adjusted EBITDA is 3.1x — above the 2–3x target — inflated by $61 million of buybacks (2.2 million shares) executed in the same quarter that trailing EBITDA fell. Ex-repurchase it would be 3.0x. Buying stock at a 3.1x leverage multiple while guiding down is a confident signal, but it leaves the acquisition funnel management keeps advertising largely theoretical for now.if I were modeling things for myself, I would that it is probably about half the benefit is gonna come from COGS. Because if you think about COGS, it is the it is obviously material and labor but there is also indirect costs